Navigation Links
Favrille Reports Fourth Quarter and Year End 2007 Financial Results
Date:2/19/2008

ons through the primary endpoint analysis in our Phase 3 clinical registration trial, which we expect no later than July 2008," said Tamara A. Seymour, Chief Financial Officer of Favrille.

Conference Call and Webcast Information

Favrille management will host a conference call today to discuss the fourth quarter and year end 2007 financial results at 5:00 p.m. Eastern Time. A live audio webcast of management's presentation will be available on the Investor Relations section of the Company's web site at http://www.favrille.com. Alternatively, callers may participate in the conference call by dialing (888) 713-4213 or (617) 213-4865, passcode 19388148. To pre-register for this call, please go to https://www.theconferencingservice.com/prereg/key.process?key=P9YHNKNHB. Callers who pre-register will be given a unique PIN to gain immediate access to the call and bypass the live operator. You may pre-register at any time, including up to and after the call start time. A telephone replay of the call will also be available for 48 hours. The telephone replay can be accessed by dialing (888) 286-8010 or (617) 801-6888, passcode 99385491.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, Specifid (mitumprotimut-T, formerly FavId), is based upon unique genetic information extracted from a patient's tumor. Specifid is currently under clinical investigation in a Phase 3 registration trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manu
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille Announces $21.1 Million Registered Direct Offering
2. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
3. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
4. Favrille to Present at BIO InvestorForum
5. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
6. Favrille CEO to Present at Bear Stearns Healthcare Conference
7. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
8. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
9. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Bellingham, Washington, USA, and Cardiff, UK (PRWEB) January 13, ... and photonics technology development leader with more than 20 ... international society for optics and photonics . Hainsey will ... “We are delighted to have Dr. Hainsey join SPIE ...
(Date:1/14/2014)... Rochester, NY (PRWEB) January 14, 2014 During ... is now known as “The Doctor’s Plague.” In this time ... their hands. This led, at times, to the death of ... staff today don’t know that they may be unwittingly transmitting ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of ... and novel disease specific POC tests, announced today that it ... total of $690,000. The investment is from private investors and ... group of private investors has significant successful experience in early ...
(Date:1/14/2014)... City, Panama (PRWEB) January 14, 2014 ... has received the county’s first clinical trial approval ... umbilical cord-derived mesenchymal stem cells (MSC) from the ... Review Board (IRB). , Rheumatoid Arthritis (RA) is ...
Breaking Biology Technology:Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 3
... OAB Drug in China, PLYMOUTH MEETING, Pa., ... BJGP ) ("BMP Sunstone" or the "Company") today,announced ... was officially accepted by China,s State Food & ... requirement prior to,pursuing a clinical trial and, ultimately, ...
... Programs Supported by a Grant from Otsuka ... America Pharmaceutical, Inc., ROCKVILLE, ... nonprofit organizations and one individual,as the recipients of the fifth annual ... the 2008 APF Annual Benefit in,Washington, D.C. Each organization or individual ...
... 6 Biomatrica, the leader in room,temperature biological sample ... as Vice President of Sales and Marketing.,Biomatrica,s interim Vice ... integral part of the company and will continue to ... Ms. Dowling brings fourteen years of sales and marketing ...
Cached Biology Technology:BMP Sunstone Receives SFDA Acceptance for Enablex(R) Clinical Trial 2BMP Sunstone Receives SFDA Acceptance for Enablex(R) Clinical Trial 3American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health 2American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health 3American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health 4American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health 5Trisha Dowling Joins Biomatrica as Vice President, Sales and Marketing 2
(Date:4/23/2014)... pair of bioethics experts have added "playwright" to their ... in grappling with an onslaught of ethical issues as ... the human genome was first sequenced. , Until ... W. Bush have been performed for, and by, their ... conferences, meetings and in classrooms. With Oxford University ...
(Date:4/23/2014)... ripping open a dinner roll, a fuel cell catalyst ... hydrogen molecule. Now researchers have captured a view of ... its hydrogen feast. The view confirms previous hypotheses and ... better for alternative energy uses. , This study is ... hydrogen halves end up in the structure of a ...
(Date:4/23/2014)... source of a unique rhythmic sound, recorded for decades ... the Antarctic minke whale ( Balaenoptera bonaerensis ). First ... who thought it sounded like a duck, the bio-duck ... Southern Ocean, but its source has remained a mystery, ... of researchers deployed acoustic tags on two Antarctic minke ...
Breaking Biology News(10 mins):Bioethicists use theatrical narratives to bridge the gap between society and science 2Bioethicists use theatrical narratives to bridge the gap between society and science 3Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3
... from the University of Copenhagen and the Technical University ... the US found that the bacterium Pseudomonas aeruginosa ... white blood cells preventing the bacteria being eliminated ... aeruginosa is responsible for many hospital-acquired infections and ...
... 2009 / b3c newswire /- PlatformQ , ... healthcare, education and energy markets, and LabRoots , a ... that Mark Vachon, the President and CEO for GE Healthcares ... Thursday November 19th at 2:00 PM. GE Healthcare ...
... Rockville, Md. (Oct. 30, 2009) A collaborative research team ... Australian Animal Health Laboratory and National Cancer Institute, a component ... forward in the development of an effective therapy against two ... results of this finding appear Oct. 30, 2009, in the ...
Cached Biology News:Bacteria 'launch a shield' to resist attack 2GE Healthcare President & CEO, Mark Vachon, to Present at BioConference Live 2USU scientists report major advance in human antibody therapy against deadly Nipah virus 2USU scientists report major advance in human antibody therapy against deadly Nipah virus 3
... developed specifically for the stabilization of ... plates/strips. Coating Stabilizer maintains the ... or protein antigen portion of the ... filtered at 0.2 microns., ,Contents: ...
... Novagen's HT96 Isothermal Block is an ... hold HT96 plates and to provide efficient ... plate. This new design of the HT96 ... offers an enhanced product design allowing for ...
Umbilical cord blood neutrophils, For immunohistochemistry (IHC)...
...
Biology Products: